PYXS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
-100.0%
11.0M
0
-100.0%
2.8M
Cost of Revenue
0
0
-100.0%
2.4M
0
0
Gross Profit
0
0
-100.0%
8.7M
0
-100.0%
2.8M
Operating Expenses
26.0M
+6.7%
24.4M
-9.6%
26.9M
+14.9%
23.5M
+3.9%
22.6M
R&D
16.1M
-19.6%
20.0M
-8.0%
21.7M
+21.9%
17.8M
+3.9%
17.1M
SG&A
9.9M
+126.9%
4.4M
-16.4%
5.2M
-7.4%
5.7M
+4.0%
5.4M
Operating Income
-25990000
-6.7%
-24360000
-33.2%
-18295000
+22.0%
-23461000
-18.8%
-19750000
EBITDA
-25689000
-7.5%
-23901000
-55.2%
-15398000
+32.9%
-22934000
-19.4%
-19215000
Net Income
-25346000
-8.9%
-23272000
-28.5%
-18106000
+17.7%
-22003000
-19.9%
-18354000
EPS (Basic)
$-0.40
-8.1%
$-0.37
-27.6%
$-0.29
+17.1%
$-0.35
-16.7%
$-0.30
EPS (Diluted)
$-0.40
-8.1%
$-0.37
-27.6%
$-0.29
+17.1%
$-0.35
-16.7%
$-0.30
Shares (Diluted)
64.0M
+0.8%
63.5M
+0.7%
63.0M
+0.8%
62.6M
+1.0%
61.9M
Pyxis Oncology (PYXS) โ€” Financials